CN108698992B - 用于治疗癌症的2-氰基异吲哚啉衍生物 - Google Patents

用于治疗癌症的2-氰基异吲哚啉衍生物 Download PDF

Info

Publication number
CN108698992B
CN108698992B CN201780009130.3A CN201780009130A CN108698992B CN 108698992 B CN108698992 B CN 108698992B CN 201780009130 A CN201780009130 A CN 201780009130A CN 108698992 B CN108698992 B CN 108698992B
Authority
CN
China
Prior art keywords
carbonitrile
cyano
dihydro
pyrrolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780009130.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108698992A (zh
Inventor
K·R·吉布森
A·琼斯
M·I·肯普
A·马丁
M·L·施托克利
G·A·惠特洛克
M·D·伍德罗
K·A·米尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CN108698992A publication Critical patent/CN108698992A/zh
Application granted granted Critical
Publication of CN108698992B publication Critical patent/CN108698992B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
CN201780009130.3A 2016-03-18 2017-03-17 用于治疗癌症的2-氰基异吲哚啉衍生物 Active CN108698992B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1604647.6 2016-03-18
GBGB1604647.6A GB201604647D0 (en) 2016-03-18 2016-03-18 Novel compounds
PCT/GB2017/050763 WO2017158388A1 (en) 2016-03-18 2017-03-17 2-cyanoisoindoline derivatives for treating cancer

Publications (2)

Publication Number Publication Date
CN108698992A CN108698992A (zh) 2018-10-23
CN108698992B true CN108698992B (zh) 2022-04-19

Family

ID=55968548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780009130.3A Active CN108698992B (zh) 2016-03-18 2017-03-17 用于治疗癌症的2-氰基异吲哚啉衍生物

Country Status (7)

Country Link
US (1) US10683269B2 (https=)
EP (1) EP3429994B1 (https=)
JP (1) JP6959250B2 (https=)
CN (1) CN108698992B (https=)
GB (1) GB201604647D0 (https=)
MA (1) MA43746A (https=)
WO (1) WO2017158388A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373656B (es) 2015-03-30 2020-04-02 Mission Therapeutics Ltd Compuestos de 1-ciano-pirrolidina como inhibidores de las enzimas desubiquitinantes, como la hidrolasa 30 de la c-terminal de la ubiquitina (usp30), y el uso de los mismos en el tratamiento de condiciones de disfunción mitocondrial y tratamiento de cancér.
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
JP7208931B2 (ja) 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
CN112601584A (zh) 2018-07-24 2021-04-02 豪夫迈·罗氏有限公司 异喹啉化合物及其用途
JP7434285B2 (ja) * 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
CN109321940A (zh) * 2018-11-30 2019-02-12 西南大学 一种酰胺的电化学氧化合成方法及其应用
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
US20220041597A1 (en) * 2018-12-26 2022-02-10 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CN112538083B (zh) * 2019-09-23 2023-04-28 华东师范大学 一类靶向bcl6的芳香环并五元芳杂环类小分子有机化合物及其衍生物及其应用
CN110804041B (zh) * 2019-09-25 2023-03-31 香港科技大学深圳研究院 抗肿瘤的吲哚类化合物的制备方法及吲哚类化合物和应用
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
CN113135924B (zh) * 2020-01-19 2024-04-26 广东东阳光药业股份有限公司 嘧啶衍生物及其在药物中的应用
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
WO2021204856A1 (en) 2020-04-08 2021-10-14 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
IL298526A (en) 2020-05-28 2023-01-01 Mission Therapeutics Ltd N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
BR112022019722A2 (pt) 2020-06-04 2022-12-20 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
DK4161929T3 (da) 2020-06-08 2025-08-18 Mission Therapeutics Ltd 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
CN114053270B (zh) * 2020-08-05 2023-06-13 兰州大学第二医院 泛素结合酶e2t的小分子抑制剂
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
EP4271383A4 (en) * 2020-12-29 2024-10-23 Merck Sharp & Dohme LLC Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses
CA3230256A1 (en) * 2021-08-30 2023-03-09 Dominic Reynolds Compounds and methods for modulating splicing
US20250034122A1 (en) 2021-12-01 2025-01-30 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
KR20240132285A (ko) * 2021-12-08 2024-09-03 키네타, 인크. 비시클릭 헤테로아렌 및 그의 사용 방법
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
WO2025067111A1 (zh) * 2023-09-27 2025-04-03 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360569A (en) 1993-11-12 1994-11-01 Lever Brothers Company, Division Of Conopco, Inc. Activation of bleach precursors with catalytic imine quaternary salts
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
PL2678332T3 (pl) 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
CN103030634B (zh) 2011-09-30 2015-07-15 山东轩竹医药科技有限公司 含有并环的噁唑烷酮类抗菌素
CA2896731A1 (en) * 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN106458914B (zh) 2014-03-28 2020-01-14 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物
CR20170005A (es) 2014-07-08 2017-05-08 Viiv Healthcare Uk Ltd Derivados de insoindolina
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MX373656B (es) 2015-03-30 2020-04-02 Mission Therapeutics Ltd Compuestos de 1-ciano-pirrolidina como inhibidores de las enzimas desubiquitinantes, como la hidrolasa 30 de la c-terminal de la ubiquitina (usp30), y el uso de los mismos en el tratamiento de condiciones de disfunción mitocondrial y tratamiento de cancér.
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ubiquitin-specific proteases as cancer drug targets;Wolfgang Sippl，等;《Future Oncol》;20111231;第7卷(第5期);619-623 *

Also Published As

Publication number Publication date
WO2017158388A1 (en) 2017-09-21
EP3429994B1 (en) 2021-06-16
MA43746A (fr) 2018-11-28
GB201604647D0 (en) 2016-05-04
JP2019508467A (ja) 2019-03-28
JP6959250B2 (ja) 2021-11-02
EP3429994A1 (en) 2019-01-23
US20190010122A1 (en) 2019-01-10
US10683269B2 (en) 2020-06-16
CN108698992A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
CN108698992B (zh) 用于治疗癌症的2-氰基异吲哚啉衍生物
CN108699035B (zh) 新化合物
CN107849013B (zh) 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
CN108602823B (zh) 作为去泛素化酶（dub）抑制剂的螺-缩合吡咯烷衍生物
CN108473502B (zh) 用于治疗癌症的4,6二氢吡咯并[3,4-c]吡唑-5(1h)-腈衍生物
KR102578325B1 (ko) Usp30 억제제로서의 1-시아노-피롤리딘 화합물
EP3197883B1 (en) Novel compounds
CN102548984B (zh) Pi3激酶和/或mtor的抑制剂
TWI910484B (zh) 並環含氮化合物、其中間體、製備方法和應用
KR101921486B1 (ko) ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그
CN119301127A (zh) 6-氧代十氢吡咯并[1,2-a][1,5]二氮杂环辛四烯和6-氧代十氢-4H-吡咯并[2,1-d][1,5]硫杂氮杂环辛四烯衍生物作为STAT3和STAT6的调节剂用于治疗癌症和炎性病状
CN114340634A (zh) 作为激酶抑制剂的杂环化合物
CN110494433A (zh) 布鲁顿酪氨酸激酶抑制剂
CN111655690B (zh) 吡唑并吡啶酮化合物
CN111655689B (zh) 吡唑并吡啶酮化合物
HK40043421A (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
HK40043421B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
HK1258589B (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
HK40037152B (en) Pyrazolopyridinone compounds
HK1245266B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
HK1172024A (en) Inhibitors of pi3 kinase and/or mtor
HK1192227B (en) Thiazolopyrimidine compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant